TY - JOUR
T1 - Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics
T2 - 52-week evaluation of JUMPs, a randomized, open-label study
AU - Ishigooka, Jun
AU - Nakagome, Kazuyuki
AU - Ohmori, Tetsuro
AU - Iwata, Nakao
AU - Inada, Ken
AU - Iga, Jun ichi
AU - Kishi, Taro
AU - Fujita, Kiyoshi
AU - Kikuchi, Yuka
AU - Shichijo, Toshiaki
AU - Tabuse, Hideaki
AU - Koretsune, Shotatsu
AU - Terada, Hiroshi
AU - Terada, Haruko
AU - Kishimoto, Toshifumi
AU - Tsutsumi, Yuichiro
AU - Kanda, Yoshiki
AU - Ohi, Kazutaka
AU - Sekiyama, Kanji
N1 - Publisher Copyright:
© 2021 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.
PY - 2022/1
Y1 - 2022/1
N2 - Aim: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 52-week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality-of-life scores [Personal and Social Performance Scale (PSP) and EuroQol-5 dimensions], and safety. Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. Conclusion: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.
AB - Aim: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 52-week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality-of-life scores [Personal and Social Performance Scale (PSP) and EuroQol-5 dimensions], and safety. Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. Conclusion: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.
UR - http://www.scopus.com/inward/record.url?scp=85119074991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119074991&partnerID=8YFLogxK
U2 - 10.1111/pcn.13304
DO - 10.1111/pcn.13304
M3 - Article
C2 - 34626144
AN - SCOPUS:85119074991
SN - 1323-1316
VL - 76
SP - 22
EP - 31
JO - Psychiatry and clinical neurosciences
JF - Psychiatry and clinical neurosciences
IS - 1
ER -
